What is the benefit of increasing the sulfonylurea dose?

Article Abstract:

Greater than normal doses of the sulfonylurea compound glipizide for patients with non-insulin dependent diabetes appear to be no more effective than lower doses in controlling blood glucose levels and may even result in diminished insulin secretion. Recommended doses of glipizide range from 40 milligrams (mg) in the US to 15 mg in Europe, and few studies have been done to determine the optimum dosage for therapeutic effect. For two weeks, 23 patients with non-insulin dependent diabetes took a placebo, or inactive substance, and then for three months they took either 10 mg, 20 mg or 40 mg of glipizide. Blood glucose levels were significantly higher during placebo treatment, but did not differ significantly as glipizide dose varied. All doses of glipizide stimulated insulin secretion more than placebo, but the insulin response following a meal was greatest for 10 mg of glipizide and weakest for 40 mg.

Dosage and administration, Sulfonylurea compounds, Sulfonylureas

---

Hepatic Failure in a Patient Taking Rosiglitazone

Article Abstract:

Use of rosiglitazone, a hypoglycemic drug used to treat Type 2 diabetes, may be associated with liver failure. This drug was approved as a replacement for troglitazone, a hypoglycemic drug the use of which was was associated with liver failure, sometimes leading to liver transplant or death. In this case, a 68 year old man had been using rosiglitazone for 21 days at which time he developed liver failure. Use of the drug was discontinued and the patient was treated in intensive care with lactulose, vitamin K, fresh frozen plasma, and ventilation. He made a full recovery.

Risk factors, Physiological aspects, Liver failure, Hypoglycemic agents

---

Hepatocellular Injury in a Patient Receiving Rosiglitazone A Case Report

Article Abstract:

Rosiglitazone maleate, a hypoglycemic drug used to treat type 2 diabetes which acts by increasing sensitivity to insulin, may be involved with injury to the liver. Patients who use the drug should have their liver enzyme levels monitored sooner and more often than was first thought. A 61 year old man who had been taking rosiglitazone for two weeks had anorexia, vomiting, and abdominal pain. Tests showed severe injury to the liver. The use of rosiglitazone was stopped and the functioning of his liver quickly returned to normal along with an end to his symptoms.

Injuries, Liver

Similar abstracts:

• Abstracts: Making sense of ...parenteral nutrition in adult patients. Making sense of bowel preparation. Making sense of the care of patients with pancreatitis
• Abstracts: Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias
• Abstracts: Who you gonna call? the ABC's of choosing an MD, DO or DC. Flirting without disaster. Pressing news on elbow impingement
• Abstracts: The prevention of heart failure - a new agenda. Prevention of end-stage renal disease due to type 2 diabetes
• Abstracts: Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy. The relationship between type of alcoholic drinks consumed and death from various causes

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.